• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background

    Fungal Endocarditis Companies

    ID: MRFR/LS/3679-HCR
    85 Pages
    Rahul Gotadki
    October 2025

    Fungal endocarditis is a rare but serious condition involving the inflammation of the heart lining caused by a fungal infection. Managing fungal endocarditis often requires a combination of antifungal medications and sometimes surgical intervention. There might not be specific companies solely dedicated to fungal endocarditis treatment, but pharmaceutical companies involved in antifungal drug development may play a role. 

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Top Industry Leaders in the Fungal Endocarditis Market

    Fungal Endocarditis Market

     


    Latest Fungal Endocarditis Companies Updates:


    Amplyx Pharmaceuticals Initiates Phase 3 Trial for APX800:This promising antifungal drug candidate specifically targets Candida and Aspergillus species, common culprits in FE. Positive results could significantly impact the market.


    Roche Receives FDA Breakthrough Therapy Designation for Isavuconazole:This designation for Isavuconazole, an existing antifungal drug, highlights its potential efficacy in treating FE, potentially expanding its use and increasing market share for Roche.


    Mesa Labs Collaborates with University of Pittsburgh:The collaboration aims to develop a rapid diagnostic test for FE using a novel blood biomarker. Early detection could significantly improve patient outcomes and decrease healthcare costs.


    List of Fungal Endocarditis Key companies in the market:



    • Pfizer

    • Merck & Co.

    • Sanofi

    • Astellas Pharma, Inc.

    • GlaxoSmithKline plc

    • Novartis AG

    • Enzon Pharmaceuticals, Inc.

    • Bayer AG

    • Sigma-Aldrich

    • Abbott Laboratories